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Inhibition of Human Platelet
Phospholipase A2 by
Mono(2-ethylhexyl)phthalate
by Rosalind S. Labow,* Erin Meek,* George A. Adams,*
and Gail Rock*tf
There is evidence that the carcinogenic and teratogenic effects attributed to the plasticizer di(2-
ethylhexyl)phthalate (DEHP) are due to its major metabolite mono(2-ethylhexyl)phthalate (MEHP).
MEHP is also formed ex vivo by a plasma enzyme in blood products stored in polvinyl chloride
(PVC) DEHP plastic containers. People who receive large amounts of blood products, such as
hemophiliacs or patients undergoing hemodialysis, cardiopulmonary bypass, or massive transfusion,
are exposed to significant levels of plasticizer. In this study, the platelet was used to show that
MEHP inhibits phospholipase A2 (PIA2), one of enzymes important in the release of arachidonic
acid from membrane phospholipids. Arachidonate is the parent molecule for the synthesis of
prostaglandins, thromboxanes, leukotrienes, and lipoxins that are made by a wide variety of cells.
PIA2 was measured by the liberation of 14C-arachidonic acid from 1-stearoyl-2-[1-14Clarachidonyl-L-
3-phosphatidylcholine. MEHP inhibits PIA2 activity noncompetitively in intact human platelets and
lysates with a K; of3.7 x 104 M. DEHP does not inhibit PIA2 in whole platelets. Inhibition ofPLA2
by MEHP occurs at only three times the circulating level of MEHP measured in neonates undergoing
exchange transfusion and 20-fold the levels experienced by patients during cardiopulmonary bypass.
Therefore, infants and adult patients with multisystem failure who accumulate MEHP in their blood
may be at risk for decreased platelet function.
Introduction
The commonly used plasticizer in polyvinyl chlo-
ride (PVC) plastic, di(2-ethylhexyl)phthalate (DEHP),
is a widespread environmental contaminant. Al-
though it is a nongenotoxic carcinogen (1) since it
does not bind to DNA (2), a variety of chronic toxic
effects have been shown to occur in rats and mice when
DEHP makes up 0.6 to 1.2% of their diet. These include
embryotoxicity and teratogenicity (3), as well as car-
cinogenicity (4) and testicular atrophy (5,6). There is
substantial evidence that the toxic effects observed are
due not to the parent compound, but to one or more of
its metabolites (7,8). The initial step in the metabolism
of DEHP in vivo is its hydrolysis to mono(2-ethyl-
hexyl)phthalate (MEHP). This process also occurs
during blood storage in a plastic container (9). Thus,
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red cell concentrates (9), platelet concentrates (9), albu-
min (10), and cryoprecipitate (11) all contain DEHP
and MEHP. Although human exposure to MEHP can
occur through ingestion (12), the most direct and
concentrated exposure to MEHP is by transfusion of
blood components which have been collected and stored
in flexible plastic containers (9).
In addition, hemodialysis patients (13), hemo-
philiacs (11), and patients undergoing cardiopul-
monary bypass (14) all have measurable quantities of
circulating MEHP, which are cleared within 24 hr if
renal function is normal (14). The highest levels of
MEHP recorded were 15 gg/mL (2.7 x 10-5M) found
in infants undergoing exchange transfusions (15).
Although it is difficult to assess the chronic effects of
repeated short-term exposure to MEHP, acute effects can
be measured. The infusion of MEHP into rats was
examined and recently shown by Rock et al. to cause
hypotension followed rapidly by cardiac arrest (16).
In other studies, Tavares et al. have shown that
MEHP inhibits acetylcholine and prostaglandin
PGE2-induced contractions of a rat gastric fundus
muscle preparation (17). Tavares and Vine alsoLABOWETAL.
there was reduced production of prostaglandins and
leukotrienes in rat peritoneal leukocytes in the presence
of MEHP and suggested that MEHP may have a
similar anti-inflammatory action to aspirin (18).
However, aspirin inhibits prostaglandin production,
but not leukotriene formation, suggesting that MEHP
is operating at a level of the liberation of free
arachidonic acid (AA) from membrane phospholipids.
The arachidonic acid must first be removed from the
Sn-2 position of the phospholipids by PLA2 before it can
be metabolized to form eicosanoids. In this study,
platelets were used to study the inhibitory action of
MEHP on PLA2 in intact suspensions as well as cell
lysates. In addition, the type cf inhibition and the
inhibitor binding constants were determined for the
human platelet PLA2.
Methods
Preparation of Whole Platelets and
Platelet Lysates
Blood was collected from randomly selected normal
donors who met all criteria for blood donation of the
Canadian Red gross into the standard (citrate-phos-
phate-dextrose-adenine) CPDA-1 blood bags. The red
cells were sedimented at 400g for 7 min in a Sorvall RC-
3B centrifuge at 220C (Dupont Co., Newtown, CO). The
platelet-rich plasma (PRP) was expressed into the
platelet storage bag and then centrifuged at 1300g for
6 min at 220C in a Beckman Model J-6M (Beckman
Instruments, Inc., Fullerton, CA). All but 60 mL of the
plasma was expressed into the plasma storage bag. The
concentrated platelets were left to sit undisturbed at
room temperature for 1 hr and then resuspended for
1 hr on a Helmer platelet agitator (Forma Scientific,
Marietta, OH) at 6 cycles/min.
Aliquots (1 mL) of platelet concentrate were centri-
fuged at 1300g for 12 min. The supernatant was re-
moved and the platelets were resuspended in 0.5 mL of
0.1 M Tris (trihydroxymethylaminomethane), 2 mM
ethyleneglycoltetraacetic acid (EGTA), 2 mM ethyl-
enediaminetetraacetic acid (EDTA) (TEG) buffer, pH
9.0, which had been warmed to 370C. A platelet lysate
was prepared by overlaying the platelet pellet with 0.5
mL of TEG buffer, pH 9.0, and freezing overnight at
-200C. The platelet count of the suspension prior to
freezing or assay was determined using a Coulter
Counter Model ZBI (Coulter Electronics Inc., Hialeah,
FL).
Phospholipase A2 Assay
The phospholipase A2 (PLA2) assay procedure was a
modification of Ballou and Cheung (19,20). The assay
mixture contained water (15 ,uL), 68 mM CaCl2
(20 uL), Tris buffer, pH 9.0 (130 ,uL), and 1-stearoyl-2-[1-
"Clarachidonyl L-3-glycerophosphocholine (PC)
(Amersham Canada Ltd., Oakville, ON) (10 ,u). The
solution of PC added to the assay mixture was prepared
from a stock solution of PC, specific activity 58 mCi/
mM in toluene:ethanol (1:1). The specific activity of the
PC was adjusted by mixing the radioactive stock
solution with additional PC that was not radioactive,
evaporating this mixture to dryness under nitrogen,
and redissolving the PC in dimethyl sulfoxide
(DMSO). Each assay contained from 0.215 to 2.15
nmole of PC and approximately 40,000 cpm added in
10 ,uL of DMSO. The reaction was started by the addi-
tion of an aliquot of the whole platelet or platelet lysate
suspension (25 ,uL) and incubated at 370C for various
times. The reaction was stopped by the addition of 200
iL of ethanol containing 2% acetic acid and 20 ,ug
arachidonic acid (AA). An aliquot of 200 ,uL was spotted
in a band on a silica gel G thin-layer plate and chro-
matographed in hexane:ether:acetic acid (70:30:1). The
bands corresponding to AA and PC were visualized
with iodine vapor, scraped, and counted in 10 mL
Ready-Solv-HP scintillation cocktail (Beckman In-
struments, Inc., Toronto, Canada), in a liquid scintil-
lation counter (Model LS-7500, Beckman Instruments,
Richmond, CA).
The percentage hydrolysis was calculated by the
following equation:
% Hydrolysis =
arachidonic acid (cpm) x 100%
phosphatidylcholine (cpm) and arachidonic (cpm)
Rate of hydrolysis (nmole/min) =
% Hydrolysis x nmole phosphatidylcholine per assay
100 x incubation time (min)
The amount of arachidonic acid formed (nmole) per
minute was equivalent to the rate of hydrolysis of PC.
When the inhibition by MEHP was measured, ali-
quots of a stock solution of MEHP, 1 mg/mL in
methanol, were evaporated to dryness under nitrogen,
and the MEHP was redissolved in Tris buffer, pH 9.0,
so as to give the required amount of MEHP to be added
to the assay mixture.
Results
The kinetics of PLA2 hydrolysis of phosphatidyl-
choline (PC) to release arachidonic acid were mea-
sured in whole platelets and in platelet lysates (Fig. 1).
For whole platelets the hydrolysis was linear up to a
maximum of 5% hydrolysis and had a rate of 2 nmole
arachidonic acid formed per minute by 109 platelets at
370C. Platelet lysates hydrolyzed the PC 10% under the
same conditions producing 3.9 nmole/min/109
platelets. Freezing and thawing the platelet suspen-
sions several times did not increase the PLA2 activity
released by freezing overnight. The platelet PLA2 was
saturated at a substrate concentration of 5.4 x 10 -3M for
both lysate and whole platelet preparations and was
directly proportional to the number of platelets per
assay up to 108 platelets (data not shown).
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FIGuRE 2. Inhibition ofwhole platelets (0) and platelet lysates (LI) by
MEHP.
FIGURE 1. Effect of time on the hydrolysis of PC by whole platelet (A)
and platelet lysate ( i ) PLA2. The assay was performed as described
in "Methods," except that incubation times were increased from 10 to
40 min.
MEHP inhibited the PIA2 activity of whole platelets
as well as platelet lysates (Fig. 2). At 9.0 ± 0.92 x 10-5M
MEHP, the PLA2 activity in whole platelets was
inhibited 50%, whereas 50% inhibition of PIA2 in
platelet lysates occurred at 7.5 ± 0.07 x 10-5M. Dixon's
analysis shows that the MEHP noncompetitively
inhibits platelet PIA2 (21) (Fig. 3). The inhibitor
binding constant (K,) for PLA2 inhibition was the
same for the whole platelets and the platelet lysates, 3.7 x
104M.
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Discussion
It was possible to measure PLA2 activity in vitro using
whole platelets. Previously this assay was used to
measure the release of arachidonate from PC using
platelet homogenates (lysates) and isolated platelet
membrane preparations (19,20). The arachidonic acid
released from the PC was directly proportional to the
number of platelets per assay and followed Michaelis-
Menten kinetics. The location of PLA2 within the
platelet membrane in resting platelets has not been
defined. It is thought that PLA2 is on the inner surface
of the platelet membrane and that it becomes exposed
during platelet activation (22). The fact that it was
possible to measure hydrolysis of PC using intact
resting platelets means that some of the enzyme must
have been exposed or some ofthe platelets were lysed. As
there was a twofold increase in PLA2 activity upon
lysis, it is unlikely that small amounts of lysis during
platelet preparation gave the PLA2 activity measured in
whole platelets. Also, repeated freezing and thawing up
to five cycles gave no further increase in PLA2. This
was confirmed by the fact that the K; for MEHP was the
same for both whole platelets and platelet lysates.
MEHP x 106 M
O *50
z
25
-500
B
0 500 1000 1500
MEHP x 106 M
FIGURE 3. (A) Determination of the inhibitor constant, Ki, for MEHP
measuring whole platelet PLA2 activity at 10.8 x 10-3M PC (LO]) and
2.15 x 10-3 M PC (A\). (B) Determination of the inhibitor constant,
K., for MEHP measuring platelet lysate PLA2 activity at 10.8 x 10-3
iM PC (0) and 2.15 x 10-3M PC (A).
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PLA, is one of the enzymes involved in arachidonic
acid release from membrane phospholipids. Whether
or not it is the most important source of arachidonic
acid has not been absolutely established for human
platelets. It is possible that phospholipase C, formed by
diacylglycerol lipase, is responsible for the release of
arachidonic acid following platelet activation (22). In
any case, the fact that it was possible to measure human
platelet PLA, activity without disrupting the cell made
it an excellent system to study the toxic effects of the
plasticizer metabolite MEHP in humans.
There is accumulating evidence that it is not DEHP,
but its primary metabolite, MEHP, which is respon-
sible for the chronic toxic effects observed when DEHP
is fed to rats and mice. This is also true of the acute
inhibitory effect on PLA,,. DEHP showed no inhi-
bition of PLA. at concentrations 10-fold higher than
those of MEHP, but DEHP does not cause hypotension
and cardiac arrest in rats. When toxic effects of a
compound are observed in animals, a margin of safety
(MOS) is chosen based on the severity of the toxic end
point and the uncertainty of the data base when
extrapolating to human exposure and can vary from
100 (23) to 1000 (24). The levels that caused the toxic
effects we observed in rats corresponded to a MOS of 50
when compared to levels of exposure in a trauma
patient during massive transfusion (25). This is still
2-fold lower than the lowest acceptable MOS quoted by
Lehman and Fitzhugh (23) and 20-fold lower than a
more recently chosen MOS (24).
Since then, we have measured circulating levels of
MEHP in clinical situations such as cardiopulmo-
nary bypass and heart transplant patients (14) and
others have measured circulating levels of MEHP in
neonatal exchange transfusions (15). Concentrations
of 2.7 x 10-1 M have been measured in transfused new-
borns (15) and we have measured 4 x 10-"3M MEHP in
the blood of babies at the end of 1 hr of cardiopul-
monary bypass (14). At the K, for MEHP, 3.7 x 10-4 M,
presumably only 50% of the whole platelet PLA., is
active. This is only 14-fold higher than the values
actually measured in clinical situations. Certainly,
platelet PLA., plays an active role in the in vivo function
of human platelets. The rapid response and intricate
control mechanisms responsible for the initiation of
hemostatic plug formation involves a well-function-
ing PLA., It is very difficult to choose an acceptable
MOS when the clinical situation involves compro-
mised patients with multisystem failure.
In rats, DEHP and MEHP have low acute oral
toxicity and since these compounds were shown to be
nongenotoxic carcinogens (1), concern about the
chronic toxic effects that occur after long-term exposure
by ingestion has been alleviated. Also, elimination of
these widespread environmental contaminants from
the body occurs rapidly unless renal function is
impaired (14). However, infants and adult patients
with multisystem failure accumulate MEHP in their
blood and therefore may be at risk for decreased platelet
function.
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